Erectile Dysfunction and Diabetes: The Connection Every Man Should Know

Of all the conditions associated with erectile dysfunction, diabetes has one of the strongest and most well-documented relationships. ED affects an estimated 35-75% of men with diabetes — a prevalence two to three times higher than in the general male population — and typically develops 10-15 years earlier than in men without the condition. (Maiorino MI et al., Journal of Sexual Medicine, 2014)

Despite this, the connection between diabetes and erectile dysfunction is rarely discussed proactively in clinical practice. Men with diabetes are often prescribed PDE5 inhibitors (Viagra, Cialis) without any explanation of why these medications are less effective in their specific situation — or what the alternatives are.

This guide explains the precise biological mechanisms through which diabetes damages erectile function, why standard medication performs less well in diabetic men, and what the evidence shows about focal shockwave therapy as a treatment specifically suited to this patient group.

How Diabetes Damages Erectile Function

Diabetes causes erectile dysfunction through two distinct and simultaneous mechanisms — vascular damage and neurological damage. This combination is what makes diabetic ED both more prevalent and more challenging to treat than vasculogenic ED alone. See our full guide to every recognised cause of ED for the wider picture.

Vascular Damage

Chronic hyperglycaemia — elevated blood glucose — is directly toxic to the vascular endothelium. Over time, high blood sugar damages the inner lining of blood vessels throughout the body, impairing their ability to produce nitric oxide and dilate in response to stimulation.

In the penis, this endothelial dysfunction progressively reduces the blood flow available for erection. The penile arteries — already small at approximately 1-2mm in diameter — become narrowed, less responsive, and unable to deliver the pressure required for a firm erection. This is the same atherosclerotic mechanism that drives cardiovascular disease in diabetic patients — and the penile arteries, being the smallest vessels affected, show changes earliest.

Advanced glycation end-products (AGEs) — compounds formed when glucose binds to proteins — accumulate in the smooth muscle of the corpus cavernosum and the walls of penile arteries, further reducing elasticity and contractile capacity. (Saenz de Tejada I et al., International Journal of Impotence Research, 2004)

Neurological Damage

Diabetic peripheral neuropathy — nerve damage caused by chronic hyperglycaemia — affects the autonomic nerve fibres responsible for triggering the erectile reflex. These small unmyelinated fibres, which carry the parasympathetic signals that initiate smooth muscle relaxation and blood inflow, are among the earliest peripheral nerves to be affected by diabetic neuropathy.

When these nerve pathways are damaged, the initial signal that triggers nitric oxide release and smooth muscle relaxation is impaired or absent — regardless of how healthy the blood vessels might otherwise be. This neurogenic component of diabetic ED is often underrecognised and undertreated.

Hormonal Contribution

Men with type 2 diabetes have significantly higher rates of testosterone deficiency (hypogonadism) than the general male population — with some studies reporting prevalence of low testosterone in 25-50% of men with type 2 diabetes. (Corona G et al., Journal of Sexual Medicine, 2011) Low testosterone reduces libido and contributes to erectile dysfunction through both central and peripheral mechanisms, adding a third layer to the complexity of diabetic ED — see our Low Libido & Sexual Wellness service.

Why Viagra Works Less Well in Diabetic Men

PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) — are the standard first-line treatment for ED. In the general male population, response rates are approximately 70-80%. In men with diabetes, response rates fall to 40-60% — a clinically significant reduction. (Hatzimouratidis K et al., European Urology, 2010)

The reason is mechanistic. PDE5 inhibitors work by blocking the enzyme that breaks down cyclic GMP — the chemical messenger responsible for smooth muscle relaxation and blood inflow. But cyclic GMP production depends on nitric oxide. And nitric oxide production depends on healthy endothelial function.

In men with diabetes, endothelial function is impaired — nitric oxide production is reduced. PDE5 inhibitors amplify the signal from available nitric oxide, but if the endothelium is too damaged to produce adequate nitric oxide in the first place, there is insufficient substrate for the drug to work with.

Focal Shockwave Therapy for Diabetic ED: The Evidence

Focal shockwave therapy addresses both the vascular and neurogenic components of diabetic ED — making it mechanistically well-suited to this patient group. See our guide to how focal shockwave therapy works for ED for the full mechanism.

Vascular Regeneration

Low-intensity focal shockwave therapy (Li-ESWT) stimulates angiogenesis — the formation of new blood vessels — and endothelial repair in the penile tissue. The acoustic energy promotes the release of vascular endothelial growth factor (VEGF) and other angiogenic mediators, driving new capillary growth in the erectile tissue and improving blood flow independent of PDE5 activity. (Gruenwald I et al., Journal of Sexual Medicine, 2012)

Critically, this angiogenic effect does not depend on intact endothelial nitric oxide production — it creates new vessels where blood flow has been compromised, rather than relying on the existing damaged endothelium to function better.

Neuroregeneration

Emerging evidence suggests that focal shockwave therapy promotes nerve regeneration in the penile tissue — stimulating the regeneration of the small autonomic nerve fibres damaged by diabetic neuropathy. This neurogenic component of shockwave therapy's action is particularly relevant in diabetic ED, where nerve damage is a primary contributor to the condition. (Patel P et al., Urology, 2019)

Clinical Evidence in Diabetic Patients

Kalyvianakis et al., 2017 — Journal of Sexual Medicine. A randomised controlled trial specifically examining the effect of Li-ESWT in men with vasculogenic ED secondary to diabetes and cardiovascular disease. The shockwave group showed significant improvement in IIEF-EF scores compared to sham treatment — with the improvement maintained at 6-month follow-up. The authors concluded that Li-ESWT is an effective treatment option for vasculogenic ED in diabetic men.

Maiorino et al., 2014 — Journal of Sexual Medicine. A comprehensive review of ED in diabetes confirmed that while PDE5 inhibitors remain appropriate first-line treatment, their reduced efficacy in diabetic men necessitates alternative approaches — and that shockwave therapy represents a promising option for men who are poor responders to medication.

Gruenwald et al., 2014 — Journal of Sexual Medicine. In men who had stopped responding to PDE5 inhibitors — a group that includes a disproportionate number of diabetic men — 57% achieved successful intercourse following focal shockwave therapy, suggesting the treatment can restore vascular function to a level where medication becomes effective again.

The European Association of Urology formally recognises Li-ESWT as a therapeutic option for vasculogenic ED in its 2024 guidelines — including men with diabetes and cardiovascular disease.

Managing Diabetic ED: A Comprehensive Approach

Focal shockwave therapy is the most clinically targeted treatment for the vascular and neurogenic components of diabetic ED — but it works best as part of a comprehensive management approach.

• Blood glucose control — the single most important factor in preventing and slowing the progression of diabetic ED. Every percentage point reduction in HbA1c reduces the risk of microvascular complications, including the endothelial and neurological damage that drives ED.
• Cardiovascular risk factor management — high blood pressure, high cholesterol, obesity, and smoking all accelerate the vascular damage of diabetes. Controlling these slows progression and improves the durability of any treatment response.
• Testosterone assessment — given the high prevalence of testosterone deficiency in men with type 2 diabetes, a blood panel including testosterone is important in any comprehensive assessment of diabetic ED.
• Lifestyle modification — weight loss improves insulin sensitivity, reduces HbA1c, increases testosterone, and improves endothelial function. Regular aerobic exercise has demonstrated direct improvement in erectile function scores in diabetic men. (Gerbild H et al., Sexual Medicine, 2018)

Treatment Options: How They Compare in Diabetic ED

What to Expect at a Consultation for Diabetic ED

At Shockwave ReVibe Clinic, every patient with diabetic ED begins with a comprehensive specialist assessment that specifically considers the diabetic context:

• Clinical history — duration and control of diabetes, current HbA1c, medications (including antihypertensives and antidepressants commonly prescribed alongside diabetes management), cardiovascular history, symptom history, and psychosexual context
• Blood tests — in addition to the standard ED panel (testosterone, LH, FSH, prolactin, thyroid), fasting glucose, HbA1c, and lipid profile are reviewed. Where recent diabetic review blood results are available, these are incorporated
• IIEF-EF scoring — baseline erectile function score established using the validated questionnaire, allowing objective tracking of improvement throughout treatment
• Treatment discussion — all options are presented honestly, including the realistic response rates for PDE5 inhibitors in diabetic men, the evidence for focal shockwave therapy in this population, and the importance of concurrent diabetes management in optimising treatment outcomes

Initial consultation: £59. No referral needed. See our Men's Urology consultation for the full assessment pathway.

Dr Kishore Bahl is a Specialist Grade Doctor in Urology (GMC Registration: 6070860) and founder of Shockwave ReVibe Clinic, 22 Notting Hill Gate, London W11 3JE. To book a consultation, call 020 3004 0564 or visit shockwave-revibe.co.uk.

Last reviewed: August 2026